多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸
Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.
84.3分
★★★★☆
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
FRONTIER PAPERS
前沿论文 8
多发性骨髓瘤的新型免疫靶点：生物学意义与治疗潜力
Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.
69.3分
★★★☆☆
站内排序·非疗效
探索 BCMA/GPRC5D 后的治疗格局：塞利尼索、硼替佐米与地塞米松在五重难治性多发性骨髓瘤序贯免疫治疗失败后的疗效——多中心分析
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refrac
65.6分
★★★☆☆
站内排序·非疗效
靶向 BCMA 或 GPRC5D 的双特异性抗体在 CAR-T 细胞治疗后复发多发性骨髓瘤中高度有效
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
65.5分
★★★☆☆
站内排序·非疗效
ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳：一项法国真实世界研究
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
63.4分
★★★☆☆
站内排序·非疗效
双特异性抗体在多发性骨髓瘤中的演进
The evolution of bispecific antibodies in multiple myeloma.
46.3分
★★★☆☆
站内排序·非疗效
SOHO 最新进展与后续问题 | 骨髓瘤早期复发的治疗：非 CAR-T 细胞
SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell.
40.6分
★★☆☆☆
站内排序·非疗效
多发性骨髓瘤靶向免疫治疗新前沿的潜力抗原
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
31.3分
★☆☆☆☆
站内排序·非疗效
共 8 条